SETD2
Histone-lysine N-methyltransferase SETD2
Also known as: FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A, SETD2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BYW2
- Gene
- SETD2
- Ensembl
- ENSG00000181555
- Chromosome
- 3
- Canonical length
- 2564 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nuclear speckles,Cytosol
OverviewNCBI Gene
Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expansion of a polyglutamine tract in the HD protein huntingtin. This gene encodes a protein belonging to a class of huntingtin interacting proteins characterized by WW motifs. This protein is a histone methyltransferase that is specific for lysine-36 of histone H3, and methylation of this residue is associated with active chromatin. This protein also contains a novel transcriptional activation domain and has been found associated with hyperphosphorylated RNA polymerase II. [provided by RefSeq, Aug 2008]
Canonical amino-acid sequenceUniProt
2564 residues, UniProt reviewed canonical sequence.
>Q9BYW2|SETD2
1 MKQLQPQPPP KMGDFYDPEH PTPEEEENEA KIENVQKTGF IKGPMFKGVA SSRFLPKGTK
61 TKVNLEEQGR QKVSFSFSLT KKTLQNRFLT ALGNEKQSDT PNPPAVPLQV DSTPKMKMEI
121 GDTLSTAEES SPPKSRVELG KIHFKKHLLH VTSRPLLATT TAVASPPTHA APLPAVIAES
181 TTVDSPPSSP PPPPPPAQAT TLSSPAPVTE PVALPHTPIT VLMAAPVPLP VDVAVRSLKE
241 PPIIIVPESL EADTKQDTIS NSLEEHVTQI LNEQADISSK KEDSHIGKDE EIPDSSKISL
301 SCKKTGSKKK SSQSEGIFLG SESDEDSVRT SSSQRSHDLK FSASIEKERD FKKSSAPLKS
361 EDLGKPSRSK TDRDDKYFSY SKLERDTRYV SSRCRSERER RRSRSHSRSE RGSRTNLSYS
421 RSERSHYYDS DRRYHRSSPY RERTRYSRPY TDNRARESSD SEEEYKKTYS RRTSSHSSSY
481 RDLRTSSYSK SDRDCKTETS YLEMERRGKY SSKLERESKR TSENEAIKRC CSPPNELGFR
541 RGSSYSKHDS SASRYKSTLS KPIPKSDKFK NSFCCTELNE EIKQSHSFSL QTPCSKGSEL
601 RMINKNPERE KAGSPAPSNR LNDSPTLKKL DELPIFKSEF ITHDSHDSIK ELDSLSKVKN
661 DQLRSFCPIE LNINGSPGAE SDLATFCTSK TDAVLMTSDD SVTGSELSPL VKACMLSSNG
721 FQNISRCKEK DLDDTCMLHK KSESPFRETE PLVSPHQDKL MSMPVMTVDY SKTVVKEPVD
781 TRVSCCKTKD SDIYCTLNDS NPSLCNSEAE NIEPSVMKIS SNSFMNVHLE SKPVICDSRN
841 LTDHSKFACE EYKQSIGSTS SASVNHFDDL YQPIGSSGIA SSLQSLPPGI KVDSLTLLKC
901 GENTSPVLDA VLKSKKSSEF LKHAGKETIV EVGSDLPDSG KGFASRENRR NNGLSGKCLQ
961 EAQEEGNSIL PERRGRPEIS LDERGEGGHV HTSDDSEVVF SSCDLNLTME DSDGVTYALK
1021 CDSSGHAPEI VSTVHEDYSG SSESSNDESD SEDTDSDDSS IPRNRLQSVV VVPKNSTLPM
1081 EETSPCSSRS SQSYRHYSDH WEDERLESRR HLYEEKFESI ASKACPQTDK FFLHKGTEKN
1141 PEISFTQSSR KQIDNRLPEL SHPQSDGVDS TSHTDVKSDP LGHPNSEETV KAKIPSRQQE
1201 ELPIYSSDFE DVPNKSWQQT TFQNRPDSRL GKTELSFSSS CEIPHVDGLH SSEELRNLGW
1261 DFSQEKPSTT YQQPDSSYGA CGGHKYQQNA EQYGGTRDYW QGNGYWDPRS GRPPGTGVVY
1321 DRTQGQVPDS LTDDREEEEN WDQQDGSHFS DQSDKFLLSL QKDKGSVQAP EISSNSIKDT
1381 LAVNEKKDFS KNLEKNDIKD RGPLKKRRQE IESDSESDGE LQDRKKVRVE VEQGETSVPP
1441 GSALVGPSCV MDDFRDPQRW KECAKQGKMP CYFDLIEENV YLTERKKNKS HRDIKRMQCE
1501 CTPLSKDERA QGEIACGEDC LNRLLMIECS SRCPNGDYCS NRRFQRKQHA DVEVILTEKK
1561 GWGLRAAKDL PSNTFVLEYC GEVLDHKEFK ARVKEYARNK NIHYYFMALK NDEIIDATQK
1621 GNCSRFMNHS CEPNCETQKW TVNGQLRVGF FTTKLVPSGS ELTFDYQFQR YGKEAQKCFC
1681 GSANCRGYLG GENRVSIRAA GGKMKKERSR KKDSVDGELE ALMENGEGLS DKNQVLSLSR
1741 LMVRIETLEQ KLTCLELIQN THSQSCLKSF LERHGLSLLW IWMAELGDGR ESNQKLQEEI
1801 IKTLEHLPIP TKNMLEESKV LPIIQRWSQT KTAVPPLSEG DGYSSENTSR AHTPLNTPDP
1861 STKLSTEADT DTPKKLMFRR LKIISENSMD SAISDATSEL EGKDGKEDLD QLENVPVEEE
1921 EELQSQQLLP QQLPECKVDS ETNIEASKLP TSEPEADAEI EPKESNGTKL EEPINEETPS
1981 QDEEEGVSDV ESERSQEQPD KTVDISDLAT KLLDSWKDLK EVYRIPKKSQ TEKENTTTER
2041 GRDAVGFRDQ TPAPKTPNRS RERDPDKQTQ NKEKRKRRSS LSPPSSAYER GTKRPDDRYD
2101 TPTSKKKVRI KDRNKLSTEE RRKLFEQEVA QREAQKQQQQ MQNLGMTSPL PYDSLGYNAP
2161 HHPFAGYPPG YPMQAYVDPS NPNAGKVLLP TPSMDPVCSP APYDHAQPLV GHSTEPLSAP
2221 PPVPVVPHVA APVEVSSSQY VAQSDGVVHQ DSSVAVLPVP APGPVQGQNY SVWDSNQQSV
2281 SVQQQYSPAQ SQATIYYQGQ TCPTVYGVTS PYSQTTPPIV QSYAQPSLQY IQGQQIFTAH
2341 PQGVVVQPAA AVTTIVAPGQ PQPLQPSEMV VTNNLLDLPP PSPPKPKTIV LPPNWKTARD
2401 PEGKIYYYHV ITRQTQWDPP TWESPGDDAS LEHEAEMDLG TPTYDENPMK ASKKPKTAEA
2461 DTSSELAKKS KEVFRKEMSQ FIVQCLNPYR KPDCKVGRIT TTEDFKHLAR KLTHGVMNKE
2521 LKYCKNPEDL ECNENVKHKT KEYIKKYMQK FGAVYKPKED TELELocalizationUniProt · AlphaFold · HPA
Whether an antibody against SETD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.55
- Highest tissue expression
- 25 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 25 nTPM
- thymus: 24 nTPM
- parathyroid gland: 23 nTPM
- ovary: 18 nTPM
- tongue: 18 nTPM
- tonsil: 17 nTPM
Single-cell type
- neutrophil progenitors: 550 nCPM
- neutrophils: 535 nCPM
- myonuclei: 410 nCPM
- thymocytes: 356 nCPM
- renal collecting duct intercalated cells: 324 nCPM
- choroid plexus epithelial cells: 317 nCPM
Immune cell
- eosinophil: 3.7 nTPM
- neutrophil: 3.7 nTPM
- NK-cell: 3.7 nTPM
- naive B-cell: 2.7 nTPM
- memory B-cell: 2.5 nTPM
- plasmacytoid DC: 2.5 nTPM
Brain region
- cerebellum: 65 nTPM
- white matter: 39 nTPM
- choroid plexus: 36 nTPM
- basal ganglia: 35 nTPM
- medulla oblongata: 32 nTPM
- midbrain: 31 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SETD2.
Disease | AllUniProt
Conditions SETD2 is implicated in, by any mechanism.
- Renal cell carcinoma (RCC) MIM:144700
- Luscan-Lumish syndrome (LLS) MIM:616831
- Leukemia, acute lymphoblastic (ALL) MIM:613065
- Leukemia, acute myelogenous (AML) MIM:601626
- Intellectual developmental disorder, autosomal dominant 70 (MRD70) MIM:620157
- Rabin-Pappas syndrome (RAPAS) MIM:620155
Disease | GeneticClinVar
72 pathogenic / likely-pathogenic of 1,535 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Luscan-Lumish syndrome
- Inborn genetic diseases
- SETD2-related disorder
- Neoplasm
- Intellectual developmental disorder, autosomal dominant 70
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.21
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.05
- DepMap mean gene effect
- -0.46
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- defense response to virus
- endodermal cell differentiation
- microtubule cytoskeleton organization involved in mitosis
- mismatch repair
- nucleosome organization
- peptidyl-lysine trimethylation
- positive regulation of autophagy
- positive regulation of interferon-alpha production
- positive regulation of ossification
- regulation of cytokinesis
- regulation of DNA-templated transcription
- regulation of double-strand break repair via homologous recombination
- regulation of gene expression
- regulation of mRNA export from nucleus
- regulation of protein localization to chromatin
- response to alkaloid
- response to metal ion
- response to type I interferon
- stem cell differentiation
- transcription elongation by RNA polymerase II
Molecular functions
- alpha-tubulin binding
- histone H3 methyltransferase activity
- histone H3K36 methyltransferase activity
- histone H3K36 trimethyltransferase activity
- metal ion binding
- protein-lysine N-methyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- WW domain
- SET domain
- Post-SET domain
- AWS domain
- Set2 Rpb1 interacting domain
- TFIIS/LEDGF domain superfamily
- WW domain superfamily
- SET domain superfamily
- WW domain
- SET domain
- SRI (Set2 Rpb1 interacting) domain
- AWS domain
- Set2 Rpb1 interacting domain superfamily
- Histone-lysine N-methyltransferase SETD2, animal
- SETD2/Set2, SET domain
KeywordsUniProt
- Activator
- Antiviral defense
- Autism spectrum disorder
- Chromatin regulator
- Chromosome
- Coiled coil
- Developmental protein
- Differentiation
- DNA damage
- DNA repair
- Host-virus interaction
- Immunity
- Innate immunity
- Intellectual disability
- Isopeptide bond
- Metal-binding
- Methyltransferase
- Nucleus
- Phosphoprotein
- S-adenosyl-L-methionine
- Transcription
- Transcription regulation
- Transferase
- Tumor suppressor
- Ubl conjugation
- Zinc
InteractionsUniProt · HPA
Protein binding partners of SETD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SETD2 as an antibody target. Whether an autoantibody or antibody against SETD2 could matter depends on whether native SETD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SETD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SETD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...